| Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies PM Maciocia, PA Wawrzyniecka, B Philip, I Ricciardelli, AU Akarca, ... Nature medicine 23 (12), 1416-1423, 2017 | 228 | 2017 |
| An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma L Lee, B Draper, N Chaplin, B Philip, M Chin, D Galas-Filipowicz, ... Blood, The Journal of the American Society of Hematology 131 (7), 746-758, 2018 | 159 | 2018 |
| Pain assessment in the paediatric Emergency Department: whose view counts? PM Maciocia, EM Strachan, AR Akram, RE Hendrie, DN Kelly, A Kemp, ... European Journal of Emergency Medicine 10 (4), 264-267, 2003 | 53 | 2003 |
| Real‐world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi‐centre UK experience N Maciocia, A Melville, S Cheesman, F Sharpley, K Ramasamy, ... British journal of haematology 176 (6), 908-917, 2017 | 32 | 2017 |
| Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia PM Maciocia, PA Wawrzyniecka, NC Maciocia, A Burley, T Karpanasamy, ... Blood, The Journal of the American Society of Hematology 140 (1), 25-37, 2022 | 31 | 2022 |
| Treatment of diffuse large B‐cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS‐penetrating R‐IDARAM chemotherapy P Maciocia, M Badat, S Cheesman, S D'Sa, R Joshi, J Lambert, ... British journal of haematology 172 (4), 545-553, 2016 | 27 | 2016 |
| Protein-based T-cell receptor knockdown P Martin, P Maciocia, B Grimshaw US Patent 10,730,942, 2020 | 13 | 2020 |
| Chimeric antigen receptor T cells for gamma–delta T cell malignancies PA Wawrzyniecka, L Ibrahim, G Gritti, MA Pule, PM Maciocia Leukemia 36 (2), 577-579, 2022 | 11 | 2022 |
| Chimeric antigen receptor M Pulé, P Maciocia US Patent App. 15/123,287, 2017 | 11 | 2017 |
| Anti-CD1a CAR T cells to selectively target T-ALL PM Maciocia, MA Pule Blood, The Journal of the American Society of Hematology 133 (21), 2246-2247, 2019 | 9 | 2019 |
| Inflammatory signaling in pulmonary arterial hypertension: The controversial role of CRP, and the search for new therapies PM Maciocia Cardiovascular therapeutics 28 (1), 1-4, 2010 | 9 | 2010 |
| Structure guided engineering of highly specific chimeric antigen receptors for the treatment of T cell lymphomas S Onuoha, M Ferrari, A Bulek, R Bughda, S Manzoor, S Srivastava, B Ma, ... Blood 132, 1661, 2018 | 7 | 2018 |
| Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region P Martin, P Maciocia | 6 | 2015 |
| Anti-CD21 chimeric antigen receptor (CAR)-T cells for t cell acute lymphoblastic leukaemia (T-ALL) NC Maciocia, A Burley, F Nannini, P Wawrzyniecka, M Neves, ... Blood 138, 902, 2021 | 5 | 2021 |
| T-cell receptor constant region 1 antibody or T-cell receptor constant region 2 antibody M Pulé, S Onuoha, AM Neves, M Ferrari, P Maciocia US Patent 11,945,867, 2024 | 4 | 2024 |
| Methods of depleting malignant T-cells M Pulé, P Maciocia US Patent 11,385,233, 2022 | 4 | 2022 |
| Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies M Ferrari, M Righi, V Baldan, P Wawrzyniecka, A Bulek, A Kinna, B Ma, ... Nature Communications 15 (1), 1583, 2024 | 3 | 2024 |
| Targeting TRBC1 and 2 for the treatment of T cell lymphomas M Ferrari, V Baldan, P Ghongane, A Nicholson, R Bughda, Z Akbar, ... Cancer Research 80 (16_Supplement), 2183-2183, 2020 | 3 | 2020 |
| A protein-based method to develop allogeneic chimeric antigen receptor T-cells P Maciocia, P Wawrzyniecka, L Kassimatis, M Pule Blood 132, 700, 2018 | 3 | 2018 |
| Targeting T-cell receptor β-constant domain for immunotherapy of T-cell malignancies PM Maciocia, P Wawrzyniecka, B Philip, I Ricciardelli, AU Akarca, ... Blood 128 (22), 811, 2016 | 3 | 2016 |
